Blue Whale Capital LLP Invests $24.34 Million in Repligen Corporation $RGEN

Key Points

• Blue Whale Capital initiated a $24.34 million Repligen stake, purchasing 178,377 shares and making the biotechnology company its 23rd-largest holding. Institutional investors collectively own 97.64% of Repligen.
• Repligen exceeded quarterly expectations, reporting $0.54 in EPS versus a $0.45 consensus and $204.13 million in revenue, up 11.9% year over year. The company issued fiscal 2026 EPS guidance of $2.03–$2.09.
• Analysts maintain a consensus “Buy” rating with a $166.43 target price, while the stock recently opened at $181.13—above the consensus target and near its 12-month high of $188.73.

Blue Whale Capital LLP bought a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 178,377 shares of the biotechnology company's stock, valued at approximately $24,338,000. Repligen accounts for about 0.8% of Blue Whale Capital LLP's holdings, making the stock its 23rd largest holding. Blue Whale Capital LLP owned 0.32% of Repligen as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Avidity Partners Management LP lifted its holdings in Repligen by 54.7% in the first quarter. Avidity Partners Management LP now owns 77,800 shares of the biotechnology company's stock worth $9,166,000 after buying an additional 27,500 shares during the period. Swedbank AB purchased a new position in shares of Repligen during the 4th quarter worth approximately $4,146,000. B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Repligen during the 2nd quarter worth approximately $3,597,000. Conestoga Capital Advisors LLC raised its position in shares of Repligen by 10.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,057,975 shares of the biotechnology company's stock worth $173,360,000 after acquiring an additional 101,062 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in shares of Repligen in the 2nd quarter worth approximately $655,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Performance

Repligen stock opened at $181.13 on Monday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $10.22 billion, a P/E ratio of 248.12, a PEG ratio of 3.31 and a beta of 1.03. The stock's 50 day moving average is $147.16 and its 200 day moving average is $131.75.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same period in the previous year, the company posted $0.26 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Jefferies Financial Group restated a "hold" rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. HSBC decreased their price objective on Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. Wolfe Research began coverage on Repligen in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $145.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $165.00 to $175.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. Finally, Barclays upped their target price on shares of Repligen from $145.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $166.43.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company's stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source